Agenda – 3rd Payer Partnership Forum

We are currently shaping the agenda for the 3rd Payer Partnership Forum in order to identify current trends, areas of interest and common challenges so we can be sure the topics selected for sessions reflect the industry’s needs and wants. If you’d like to be involved in this process and/or get involved as a speaker, panelist or roundtable moderator, please contact Mercy Lister at 917-242-3890 at mlister@exlevents.com.

  • Data Infrastructure
    • Uniting clinical patient data with claims data
    • Developing data and technological infrastructure
    • Creating patient profiles with 360 views of risk populations
    • Defining data metrics to create mutually understood communication
    • Reducing data duplication through coordinated data analysis
    • Consider data from cost-of-care to determine where patient education and adherence programs are needed
  • Incentives for Payer Partnerships
    • Compare the different perspectives and incentives depending on the partner (health system, payer, pharma)
    • Compare the advantages and disadvantages of value-based pricing and value-based reimbursement
    • Define how improved health outcomes for the population, not just reducing costs, benefits all three parties
    • Clarify the patient management/case management needs and skills of all partners
  • Initiating Partnerships
    • Deciding the facilitator or joint-operating committee of the partnership
    • Building trust between partners
    • Choosing goals and methods that achieve both parties’ long-term objectives
    • Create strategies to ensure company-wide understanding of the agreement (organizational discipline)
    • Define the metrics used to measure success of the partnership
  • Telehealth
    • Use telehealth to manage populations and share data
    • Monitor at-risk populations, medication adherence, and engagement through telehealth to reduce costs
  • Varying Metrics and Structures of Partnerships
    • Compare and contrast the different values that concern payers depending on the type of partnership (value-based, risk-based, outcomes-based)
    • Changing pharma’s position from a seller to a partner
    • The changing value of net-cost and rebates in varying partnerships
    • Role of HEOR and real-world evidence